Correction: Pharmacokinetic Characteristics, Pharmacodynamic Effect and In Vivo Antiviral Efficacy of Liver-Targeted Interferon Alpha

@inproceedings{Rycroft2015CorrectionPC,
  title={Correction: Pharmacokinetic Characteristics, Pharmacodynamic Effect and In Vivo Antiviral Efficacy of Liver-Targeted Interferon Alpha},
  author={Daniel J. Rycroft and Jane K. Sosabowski and Edward Coulstock and Marie L Davies and John D. Morrey and Sarah L. Friel and Fiona Kelly and Robert K. Hamatake and Milan Ove{\vc}ka and Rob D Prince and Laura J. Goodall and Armin Sepp and A. Nimmo Walker},
  booktitle={PloS one},
  year={2015}
}
Interferon alpha (IFNα) is used for the treatment of hepatitis B virus infection, and whilst efficacious, it is associated with multiple adverse events caused by systemic exposure to interferon. We therefore hypothesise that targeting IFN directly to the intended site of action in the liver would reduce exposure in blood and peripheral tissue and hence… CONTINUE READING